| Application of transient elastography in nonalcoholic fatty liver disease X Zhang, GLH Wong, VWS Wong Clinical and molecular hepatology 26 (2), 128, 2019 | 119 | 2019 |
| Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease X Zhang, GLH Wong, TCF Yip, YK Tse, LY Liang, VWK Hui, H Lin, GL Li, ... Hepatology, 2021 | 72 | 2021 |
| Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease H Lin, X Zhang, G Li, GLH Wong, VWS Wong Journal of Clinical and Translational Hepatology 9 (6), 972, 2021 | 59 | 2021 |
| Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease X Zhang, GBB Goh, WK Chan, GLH Wong, JG Fan, WK Seto, YH Huang, ... Liver International 40 (11), 2719-2731, 2020 | 50 | 2020 |
| Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease H Lin, TCF Yip, X Zhang, G Li, YK Tse, VWK Hui, LY Liang, JCT Lai, ... Hepatology 77 (2), 573-584, 2023 | 39 | 2023 |
| Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease X Zhang, GLH Wong, TCF Yip, JTK Cheung, YK Tse, VWK Hui, H Lin, ... Hepatology, 2022 | 39 | 2022 |
| Gut microbial metabolite TMAO increases peritoneal inflammation and peritonitis risk in peritoneal dialysis patients LEI Zhang, F Xie, H Tang, X Zhang, J Hu, X Zhong, N Gong, Y Lai, M Zhou, ... Translational Research 240, 50-63, 2022 | 37 | 2022 |
| Trimethylamine-N-oxide aggravates kidney injury via activation of p38/MAPK signaling and upregulation of HuR Y Lai, H Tang, X Zhang, Z Zhou, M Zhou, Z Hu, F Zhu, L Zhang, J Nie Kidney and Blood Pressure Research 47 (1), 61-71, 2022 | 37 | 2022 |
| Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma GLH Wong, VWK Hui, TCF Yip, LY Liang, X Zhang, YK Tse, JCT Lai, ... Alimentary Pharmacology & Therapeutics 56 (5), 869-877, 2022 | 35 | 2022 |
| Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a … X Zhang, TCF Yip, GLH Wong, WX Leow, LY Liang, LL Lim, G Li, ... Gut 72 (12), 2364-2371, 2023 | 32 | 2023 |
| Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos (t) ide analogue‐induced hepatitis B surface antigen loss TCF Yip, VWS Wong, YK Tse, LY Liang, VWK Hui, X Zhang, GL Li, ... Alimentary Pharmacology & Therapeutics 53 (2), 321-331, 2021 | 32 | 2021 |
| U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases H Lin, GLH Wong, X Zhang, TCF Yip, K Liu, YK Tse, VWK Hui, JCT Lai, ... Clinical and molecular hepatology 28 (1), 77, 2021 | 25 | 2021 |
| Diagnostic and prognostic performance of the SAFE score in non‐alcoholic fatty liver disease G Li, H Lin, P Sripongpun, LY Liang, X Zhang, VWS Wong, GLH Wong, ... Liver International 44 (1), 15-26, 2024 | 23 | 2024 |
| Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis X Zhang, TCF Yip, YK Tse, VWK Hui, G Li, H Lin, LY Liang, JCT Lai, ... Hepatology 78 (6), 1816-1827, 2023 | 20 | 2023 |
| A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma H Lin, G Li, A Delamarre, SH Ahn, X Zhang, BK Kim, LY Liang, HW Lee, ... Clinical Gastroenterology and Hepatology 22 (3), 602-610. e7, 2024 | 15 | 2024 |
| Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory‐wide cohort study X Zhang, VWS Wong, TCF Yip, YK Tse, LY Liang, VWK Hui, GL Li, ... Hepatology communications 5 (7), 1212-1223, 2021 | 13 | 2021 |
| MAFLD fibrosis score: using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease JTK Cheung, X Zhang, GLH Wong, TCF Yip, H Lin, G Li, HHW Leung, ... Alimentary Pharmacology & Therapeutics 58 (11-12), 1194-1204, 2023 | 10 | 2023 |
| A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease H Zhang, G Targher, CD Byrne, SU Kim, VWS Wong, L Valenti, ... Hepatology international 18 (4), 1178-1201, 2024 | 6 | 2024 |
| Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic … X Mao, X Zhang, L Kam, N Chien, R Lai, KS Cheung, MF Yuen, R Cheung, ... Gut 73 (12), 2054-2061, 2024 | 5 | 2024 |
| Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: a territory‐wide study X Zhang, TCF Yip, YK Tse, VWK Hui, G Li, H Lin, LY Liang, JCT Lai, ... Alimentary Pharmacology & Therapeutics 57 (10), 1103-1116, 2023 | 5 | 2023 |
